# Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

> **NCT05660993** · PHASE2 · UNKNOWN · sponsor: **National Research Center for Hematology, Russia** · enrollment: 50 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05660993
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-19
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660993, "Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05660993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*